title: [The prognosis value of early and interim ¹⁸F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma].
abstract: OBJECTIVE
  To investigate the prognosis value of early and interim ¹⁸F-FDG-PET/CT scan in patients with diffuse large B- cell lymphoma （DLBCL） to establish the suitable criteria for evaluating posttherapeutic lesions in scans.
  
  
  METHODS
  Fifty- six newly diagnosed DLBCL patients were enrolled in the study, and underwent baseline, early and interim ¹⁸F- FDG PET/CT scans. Five- point and % ΔSUVmax criteria were used separately to interpret ¹⁸F- FDG PET/CT images. Interobserver reproducibility was assessed with the kappa test（κ）, and thresholds of %ΔSUVmax were calculated via receiver operating characteristic curve（ROC）. Survival curves were obtained using Kaplan-Meier curves and log-rank test. Cox regression analysis was used for multi-factor analysis.
  
  
  RESULTS
  Median follow-up was 24 months（6 to 42 months）. The kappa value of the five- point scale was above 0.600 with the reference background set in the liver（Score≥4）. The optimal threshold of %ΔSUVmax was 81% for early PET/CT and 74% for interim PET/CT. Survival analysis showed both early and interim PET/CT scans could predict the outcome of 56 patients with DLBCL, and 3-year PFS and OS of PET-negative patients were significantly higher than those of PET-positive ones（P<0.05）. Five-score criteria were more accurate in evaluating 3- year PFS of DLBCL patients in the interim PET/CT scan（76.79%）. %ΔSUVmax criteria were better for interpreting 3-year OS（76.79% and 83.93%）. Multi-factor analysis demonstrated that early and interim PET/CT were solid predicting factors for DLBCL patients.
  
  
  CONCLUSIONS
  Early and interim PET/CT scans could predict the outcome of patients with DLBCL, treated with R-CHOP/CHOP. Three-year OS was more accurate in early and interim PET/CT using 66 %ΔSUVmax criteria as an interpretation, while 3-year PFS was more accurate in interim PET/CT by five scores criteria.
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yuewei
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Fan
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yang
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Zhitao
authors.initials: Z
authors.lastname: Ying
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Yuqin
authors.initials: Y
authors.lastname: Song
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research（Ministry of Education/Beijing）, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xuejuan
authors.initials: X
authors.lastname: Wang
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide; D004317:Doxorubicin; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy; D049268:Positron-Emission Tomography; D011241:Prednisone; D011379:Prognosis; D012372:ROC Curve; D015203:Reproducibility of Results; D000069283:Rituximab; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D014750:Vincristine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone